Roivant’s Eric Venker trades 200,000 shares

Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported exercising stock options and selling shares on the same day.

Rhea-AI Filing Summary

Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported exercising stock options and selling shares on the same day. He exercised options for 200,000 Common Shares at an exercise price of $3.85 per share, then sold 200,000 Common Shares in open-market transactions at a weighted average price of $26.49 per share, with individual sale prices ranging from $26.35 to $26.69. Following these transactions, he directly owned 1,654,597 Common Shares and held 5,044,834 stock options.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Venker Eric

Role President & Immunovant CEO

Sold 200,000 shs ($5.30M)

Approx. gross sale proceeds $5.30M

Approx. exercise cost $770K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	200,000	$0.00	$0.00
Exercise	Common Shares	200,000	$3.85	$770K
Sale	Common Shares	200,000	$26.49	$5.30M

Holdings After Transaction: Stock Option (Right to Buy) — 5,044,834 contracts (Direct); Common Shares — 1,654,597 shares (Direct)

Footnotes (2)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $26.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
2. F2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Eric Venker report for Roivant Sciences (ROIV)?

Eric Venker reported an option exercise and a share sale. He exercised options for 200,000 Roivant Sciences Common Shares at $3.85 per share, then sold 200,000 Common Shares in open-market trades at a weighted average price of $26.49 per share.

How many Roivant Sciences shares does Eric Venker own after this Form 4?

After these transactions, Eric Venker directly owns 1,654,597 Roivant Sciences Common Shares. He also holds 5,044,834 stock options, reflecting his ongoing equity exposure to the company alongside the reported sale of 200,000 Common Shares.

At what prices did Eric Venker sell Roivant Sciences (ROIV) shares?

Eric Venker sold 200,000 Roivant Sciences Common Shares at a weighted average price of $26.49. According to the disclosure, individual trades occurred at prices ranging from $26.35 to $26.69 per share across multiple transactions.

What was the exercise price of Eric Venker’s Roivant Sciences stock options?

The exercised Roivant Sciences stock options had an exercise price of $3.85 per Common Share. Venker converted 200,000 options into 200,000 Common Shares, then sold 200,000 Common Shares in the open market on the same reported transaction date.

What role does Eric Venker hold at Roivant Sciences (ROIV)?

Eric Venker serves as President & Immunovant CEO at Roivant Sciences Ltd. His Form 4 filing details personal equity-based compensation activity, including option exercises and related share sales, reflecting how part of his compensation is tied to company stock performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 05:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Immunovant CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/13/2026		M		200,000	A	$3.85	1,854,597	D
Common Shares	02/13/2026		S		200,000	D	$26.49(1)	1,654,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.85	02/13/2026		M			200,000	(2)	04/19/2032	Common Stock	200,000	$0	5,044,834	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $26.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.